Cuifang Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Cuifang Wu has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Chunjiang Wang
Department of Pharmacy, The Third Xiangya Hospital, Central South University, Changsha, China
3 shared publications - Zuojun Li
Department of Pharmacy, The Third Xiangya Hospital, Central South University, Changsha, Hunan 410013, China
3 shared publications - Linli Sun
Department of General Surgery The Third Xiangya Hospital Central South University Changsha China
2 shared publications - Wei Sun
Department of Pharmacy The Third Xiangya Hospital Central South University Changsha China
2 shared publications - Weijin Fang
Department of Pharmacy The Third Xiangya Hospital Central South University Changsha China
2 shared publications - Dan Yi
Drug clinical trial center Zhuzhou central hospital Zhuzhou China
1 shared publication
Latest Publications
- 15 October 2021
- Published by Wiley in Journal of Clinical Pharmacy and Therapeutics
- Vol. 47 (2) , 194-199
Retrospective analysis of skin photosensitivity induced by pirfenidone
What is known and objective Knowledge regarding the association between photosensitivity and pirfenidone is based mainly on case reports. The purpose of this article was to evaluate the clinical characteristics of photosensitivity associated with pirfenidone. Methods We collected studies on photosensitivity induced by pirfenidone published from 2008 to 31 August 2021 in Chinese and English for a retrospective analysis. Results and discussion The median age was 70 years (range 57–80) in 22 patients with pirfenidone-induced photosensitivity. The dose at the onset of symptoms ranged from 600 to 2403 mg for the treatment of idiopathic pulmonary fibrosis. Pirfenidone-induced photosensitivity occurred within 1 week in some patients and up to 8 months in others. The most common clinical manifestation of photosensitivity caused by pirfenidone was itching on body parts exposed to sunlight (back of hands, face, neck, and limbs) in 15 patients followed by erythema in 13 patients. Histopathological examination revealed necrotic keratinocytes, lymphocytic inflammatory cell infiltrate, hyperkeratosis and liquefaction degeneration in 5 patients. The photosensitivity test showed a markedly decreased minimum erythema dose (MED) of 7–228 mJ/cm2 UV-B in 4 patients and 4.86–12 J/cm2 UV-A in 5 patients. The clinical symptoms were significantly improved or completely relieved with a median time of 4 weeks (range 1–8) after drug withdrawal, dose reduction or systemic and topical glucocorticoid therapy. What is new and conclusion Clinicians should be aware of the potential phototoxic effects of pirfenidone and should inform patients to take pirfenidone during (or after) a meal, avoid sun exposure, wear protective clothing, and apply broad-spectrum sunscreen with high ultraviolet UVA and UVB protection.
- 15 October 2021
- Published by Wiley in Journal of Clinical Pharmacy and Therapeutics
- Vol. 47 (2) , 194-199
Retrospective analysis of skin photosensitivity induced by pirfenidone
What is known and objective Knowledge regarding the association between photosensitivity and pirfenidone is based mainly on case reports. The purpose of this article was to evaluate the clinical characteristics of photosensitivity associated with pirfenidone. Methods We collected studies on photosensitivity induced by pirfenidone published from 2008 to 31 August 2021 in Chinese and English for a retrospective analysis. Results and discussion The median age was 70 years (range 57–80) in 22 patients with pirfenidone-induced photosensitivity. The dose at the onset of symptoms ranged from 600 to 2403 mg for the treatment of idiopathic pulmonary fibrosis. Pirfenidone-induced photosensitivity occurred within 1 week in some patients and up to 8 months in others. The most common clinical manifestation of photosensitivity caused by pirfenidone was itching on body parts exposed to sunlight (back of hands, face, neck, and limbs) in 15 patients followed by erythema in 13 patients. Histopathological examination revealed necrotic keratinocytes, lymphocytic inflammatory cell infiltrate, hyperkeratosis and liquefaction degeneration in 5 patients. The photosensitivity test showed a markedly decreased minimum erythema dose (MED) of 7–228 mJ/cm2 UV-B in 4 patients and 4.86–12 J/cm2 UV-A in 5 patients. The clinical symptoms were significantly improved or completely relieved with a median time of 4 weeks (range 1–8) after drug withdrawal, dose reduction or systemic and topical glucocorticoid therapy. What is new and conclusion Clinicians should be aware of the potential phototoxic effects of pirfenidone and should inform patients to take pirfenidone during (or after) a meal, avoid sun exposure, wear protective clothing, and apply broad-spectrum sunscreen with high ultraviolet UVA and UVB protection.
- Open Access
- 8 June 2021
- Published by Wiley in Journal of Clinical Pharmacy and Therapeutics
- Vol. 46 (5) , 1367-1372
Analysis of the clinical characteristics of acute arthritis induced by clopidogrel
What is known and objective Knowledge regarding the association between clopidogrel exposure and acute arthritis is based mainly on case reports. The purpose of this article was to assess the clinical characteristics of clopidogrel-induced acute arthritis. Methods We collected literature from 1998 to 2020 in Chinese and English on acute arthritis induced by clopidogrel for retrospective analysis. Results and discussion The median age of 21 patients (6 females and 15 males) was 63 years (range 34–77). The median time of symptom onset was 10 days (range 0.21–21) overall. The median onset time of symptoms of clopidogrel-induced arthritis was 14 days (range 3–21) and 3 days (range 0.21–7) in patients with and without a loading dose of clopidogrel, respectively. Arthralgias (100%), joint swelling (61.9%), fever (57.1%), rash (33.3%) and pruritus (28.6%) were the most common accompanying symptoms. Most cases were accompanied by different degrees of acute inflammation markers: the median ESR was 68 mm/h (range 10–120), and the median CRP was 142.4 mg/L (range 2.3–408). X-ray films were unremarkable. Symptoms disappeared completely in all patients at a median time of 4 days (range 0.17–30) after the discontinuation of clopidogrel. Prasugrel, ticagrelor and ticlopidine can be used as safe alternatives to clopidogrel in patients with clopidogrel-induced acute arthritis with no recurrence of arthritis. What is new and conclusion Clopidogrel-induced arthritis is a rare adverse reaction and should be suspected in patients with arthralgia and fever during clopidogrel use.
- 8 June 2021
- Published by Wiley in Journal of Clinical Pharmacy and Therapeutics
- Vol. 46 (5) , 1367-1372
Open AccessAnalysis of the clinical characteristics of acute arthritis induced by clopidogrel
What is known and objective Knowledge regarding the association between clopidogrel exposure and acute arthritis is based mainly on case reports. The purpose of this article was to assess the clinical characteristics of clopidogrel-induced acute arthritis. Methods We collected literature from 1998 to 2020 in Chinese and English on acute arthritis induced by clopidogrel for retrospective analysis. Results and discussion The median age of 21 patients (6 females and 15 males) was 63 years (range 34–77). The median time of symptom onset was 10 days (range 0.21–21) overall. The median onset time of symptoms of clopidogrel-induced arthritis was 14 days (range 3–21) and 3 days (range 0.21–7) in patients with and without a loading dose of clopidogrel, respectively. Arthralgias (100%), joint swelling (61.9%), fever (57.1%), rash (33.3%) and pruritus (28.6%) were the most common accompanying symptoms. Most cases were accompanied by different degrees of acute inflammation markers: the median ESR was 68 mm/h (range 10–120), and the median CRP was 142.4 mg/L (range 2.3–408). X-ray films were unremarkable. Symptoms disappeared completely in all patients at a median time of 4 days (range 0.17–30) after the discontinuation of clopidogrel. Prasugrel, ticagrelor and ticlopidine can be used as safe alternatives to clopidogrel in patients with clopidogrel-induced acute arthritis with no recurrence of arthritis. What is new and conclusion Clopidogrel-induced arthritis is a rare adverse reaction and should be suspected in patients with arthralgia and fever during clopidogrel use.
- 5 April 2021
- Published by Wiley in Journal of Clinical Pharmacy and Therapeutics
- Vol. 46 (5) , 1295-1300
Analysis of the clinical characteristics of insulin autoimmune syndrome induced by alpha‐lipoic acid
What is known and objective Alpha‐lipoic acid (ALA) is widely used as a dietary supplement and antiageing agent. Insulin autoimmune syndrome (IAS) is the most serious adverse reaction reported with the use of ALA. The purpose of this study was to explore the clinical characteristics of ALA‐induced IAS and provide a scientific reference for clinical diagnosis, treatment and prevention. Methods We collected literature on IAS cases induced by ALA for retrospective analysis in Chinese and English. Results and discussion The median age of 37 patients (28 females and 9 males) was 61 years (range 32–82). The symptoms occurred at night and in the early morning (60.7%), in the late postprandial period (50.0%) or after fasting (35.7%), within hours in some patients and up to 2 months in others after stopping ALA or during medication treatment. Autonomic nervous system symptoms (81.1%) and neurological hypoglycaemia (64.9%) are the main clinical manifestations of hypoglycaemia. The blood glucose concentration at the onset of hypoglycaemia was 2.19 mmol/L (median, range 1.09–3.52), the insulin concentration was ≥100 μIU/ml (94.6%), and the C‐peptide concentration was ≤20 ng/ml (83.3%). Testing for IgG insulin autoantibodies (IAAs) was positive in 37 patients. Pancreatic imaging was unremarkable on computed tomography (CT), magnetic resonance imaging (MRI) and abdominal sonography. Hypoglycaemia disappeared within 5 days to 8 months after withdrawing ALA alone or using corticosteroid treatment. IAA turned negative in 7 months (median; range 2–36). Follow‐up showed no recurrent hypoglycaemic episodes at 7.25 months (median; range 1–36). What is new and conclusion ALA‐induced IAS is a clinically rare autoimmune disease with hypoglycaemia that occurs during medication treatment or after drug withdrawal that should be treated promptly.
- 5 April 2021
- Published by Wiley in Journal of Clinical Pharmacy and Therapeutics
- Vol. 46 (5) , 1295-1300
Analysis of the clinical characteristics of insulin autoimmune syndrome induced by alpha‐lipoic acid
What is known and objective Alpha‐lipoic acid (ALA) is widely used as a dietary supplement and antiageing agent. Insulin autoimmune syndrome (IAS) is the most serious adverse reaction reported with the use of ALA. The purpose of this study was to explore the clinical characteristics of ALA‐induced IAS and provide a scientific reference for clinical diagnosis, treatment and prevention. Methods We collected literature on IAS cases induced by ALA for retrospective analysis in Chinese and English. Results and discussion The median age of 37 patients (28 females and 9 males) was 61 years (range 32–82). The symptoms occurred at night and in the early morning (60.7%), in the late postprandial period (50.0%) or after fasting (35.7%), within hours in some patients and up to 2 months in others after stopping ALA or during medication treatment. Autonomic nervous system symptoms (81.1%) and neurological hypoglycaemia (64.9%) are the main clinical manifestations of hypoglycaemia. The blood glucose concentration at the onset of hypoglycaemia was 2.19 mmol/L (median, range 1.09–3.52), the insulin concentration was ≥100 μIU/ml (94.6%), and the C‐peptide concentration was ≤20 ng/ml (83.3%). Testing for IgG insulin autoantibodies (IAAs) was positive in 37 patients. Pancreatic imaging was unremarkable on computed tomography (CT), magnetic resonance imaging (MRI) and abdominal sonography. Hypoglycaemia disappeared within 5 days to 8 months after withdrawing ALA alone or using corticosteroid treatment. IAA turned negative in 7 months (median; range 2–36). Follow‐up showed no recurrent hypoglycaemic episodes at 7.25 months (median; range 1–36). What is new and conclusion ALA‐induced IAS is a clinically rare autoimmune disease with hypoglycaemia that occurs during medication treatment or after drug withdrawal that should be treated promptly.